Efficacy of transdermal ketoprofen on surgical inflammation in dogs.

Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation in dogs. Despite having effective analgesic efficacy, prolonged oral administration has been associated with adverse effects. Transdermal delivery of ketoprofen has reduced the incidence of adverse effects in humans and could potentially be used in veterinary clinical medicine.

Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q Biosynthesis Disorders.

Background And Objectives: Disorders of coenzyme Q (CoQ) biosynthesis comprise a group of 11 clinically and genetically heterogeneous rare primary mitochondrial diseases. We sought to delineate clinical, biochemical, and neuroimaging features of these disorders, together with outcomes after oral CoQ supplementation and the utility of peripheral blood mononuclear cell (PBMNC) CoQ levels in monitoring therapy.

Methods: This was a retrospective cohort study, registered as an audit at a specialist pediatric hospital (Registration Number: 3318) of 14 patients with genetically confirmed CoQ biosynthesis deficiency, including 13 previously unreported cases.

Education and Communication in Veterinary Clinical Practice.

Effective communication is a hallmark of successful veterinary clinical practice [...

The Groundswell Community Surf Therapy Intervention for At-Risk Women and Changes in Body Acceptance, Resilience, and Emotional Regulation.

Background: Surf therapy combines physical activity with social support to provide a healing environment.

Objective: This exploratory pre-to post-intervention study examined the effects of a novel surf therapy program for women who experienced abuse, trauma, and/or mental illness on emotional regulation, resilience, body acceptance, and gratitude.

Methods: Twenty-seven women (ages 25 to 54; mean 36.

Risk of COVID-19 Reinfection and Vaccine Breakthrough Infection, Madera County, California, 2021.

COVID-19 vaccine efficacy has been evaluated in controlled clinical trials and serves as a benchmark for evaluating the protection acquired from prior COVID-19 infection ("natural immunity"). A cohort of persons with a prior COVID-19 infection was matched to a cohort of COVID-19 vaccinated persons and the risk of reinfection post-COVID-19 infection was compared to the risk of a COVID-19 infection post-vaccination. The hazard ratio (HR) for risk of reinfection from day 90 to 300 after initial COVID-19 infection vs.